Retifanlimab trials for Colorectal cancer

All Retifanlimab trials · All Colorectal cancer trials

Phase breakdown

Recruiting trials studying Retifanlimab for Colorectal cancer

• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
  NCT06179160 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
  NCT06149481 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
  NCT07425054 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

How many trials study Retifanlimab for Colorectal cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.